Hypothesis Statement

The cochlea ages because its two critical compartments—spiral ganglion neurons (SGNs) and the stria vascularis (SV)—adopt opposite mTORC1 setpoints: SGNs drift into a low‑activity state that limits protein synthesis and neurite maintenance, whereas the SV shifts toward high mTORC1 activity that suppresses autophagy and drives lipid overload, collapsing the endocochlear potential. Restoring each compartment to its youthful mTOR setpoint—low‑moderate for SGNs, moderate‑low for SV—should preserve hearing without the systemic trade‑offs seen with chronic rapamycin.

Mechanistic Basis

• SGN compartment: Basal mTORC1 activity supports translation of neurotrophic‑related proteins and maintains axonal integrity. Prior work shows that rapamycin reduces SGN neurite outgrowth in explants 3. With age, declining IGF‑1/insulin signaling 4 pushes mTORC1 below the threshold needed for local protein synthesis, triggering a shift toward a solitary survival mode that compromises synaptic vesicle recycling and leads to retrograde degeneration independent of hair‑cell loss 4.
• Stria vascularis compartment: The SV is a mitochondrion‑rich epithelium that relies on autophagy to recycle damaged membranes and lipid droplets. Chronic mTORC1 activation blocks autophagosome formation 1, causing accumulation of oxidized lipids and fibrotic deposits that impair Na⁺/K⁺‑ATPase and K⁺‑channel function, dropping the endocochlear potential 5). Elevated mTORC1 also heightens S6K‑mediated feedback inhibition of IRS‑1, worsening insulin resistance locally and creating a vicious cycle of metabolic stress.

Novel insight: The SV’s high metabolic rate makes it uniquely sensitive to the ratio of mTORC1 to mTORC2 activity. We propose that aging skews this ratio upward (↑C1, ↓C2), attenuating Akt‑Ser473 phosphorylation and reducing FOXO‑mediated transcription of antioxidant genes. In SGNs, the opposite shift (↓C1, relatively preserved C2) diminishes Akt‑Thr308 signaling, lowering protein synthesis capacity. Thus, the dichotomy is not merely mTORC1 level but the C1/C2 balance that dictates whether a cell leans toward anabolic “civilization” or catabolic “survival”.

Testable Predictions

1. Phospho‑signature divergence: In aged mice (24 mo), immunoblot of laser‑captured SGNs will show decreased p‑S6K (Thr389) and p‑4EBP1 (Thr37/46) but unchanged p‑Akt (Ser473), whereas SV microdissections will display increased p‑S6K and p‑4EBP1 together with reduced p‑Akt (Ser473).
2. Rescue by compartment‑specific modulation:
   • Delivering a low‑dose rapamycin‑nanoparticle conjugated to an SV‑targeting peptide (e.g., binds to Na⁺/K⁺‑ATPase β‑subunit) will lower p‑S6K in the SV, restore autophagic flux (LC3‑II/I ↑, p62 ↓), and improve endocochlear potential measured by cochlear microphonics without affecting SGN p‑S6K levels.
   • Conversely, activating mTORC1 locally in SGNs via AAV‑mediated expression of a constitutively active Rheb variant (Rheb^CA) under a neuron‑specific promoter (Synapsin‑1) will increase p‑S6K, boost neurite length in cultured explants, and delay SGN loss.
3. Behavioral outcome: Mice receiving the combined SV‑targeted rapamycin and SGN‑targeted Rheb^CA will retain auditory brainstem response (ABR) thresholds within 10 dB of young controls at 24 mo, whereas systemic rapamycin alone will preserve ABR thresholds only at high frequencies but worsen low‑frequency thresholds due to SGN toxicity.

Experimental Design

• Animals: C57BL/6J mice, young (3 mo) and aged (24 mo). Both sexes, n=10 per group.
• Interventions:
  1. SV‑targeted rapamycin: PEG‑PLGA nanoparticles (≈80 nm) coated with SV‑homing peptide (KTSDK) loaded with rapamycin (0.5 mg/kg) administered via retro‑orbital injection weekly for 8 weeks.
  2. SGN‑targeted Rheb^CA: AAV9‑Syn‑Rheb^CA‑IRES‑GFP (1×10¹¹ vg) injected into the cochlea via round‑window membrane at 20 mo.
  3. Controls: saline nanoparticles, AAV‑GFP, systemic rapamycin (2 mg/kg i.p.) .
• Readouts:
  • Laser capture microdissection followed Western blot for p‑S6K, p‑4EBP1, p‑Akt (Thr308/Ser473), LC3‑II, p62.
  • Transmission EM of SV to quantify autophagosomes and lipid droplets.
  • Cochlear microphonics and ABR testing at 4, 16, 32 kHz.
  • SGN density (NeuN+ counts) and neurite length in whole‑mount immunostaining (βIII‑tubulin).
  • Oxidized lipid staining (BODIPY‑C11) in SV.
• Statistical plan: Two‑way ANOVA (age × treatment) with Tukey post‑hoc; significance set at p<0.05.

Potential Outcomes and Falsifiability

• If predictions hold: SV‑targeted rapamycin lowers mTORC1 markers and rescues endocochlear potential; SGN‑targeted Rheb^CA raises mTORC1 markers and preserves SGN structure; combined treatment yields near‑normal ABR thresholds. This would confirm that opposing mTOR setpoints drive presbycusis and that precision tuning, not blanket inhibition, is therapeutic.
• Falsification:
  • No difference in p‑S6K or autophagy metrics between SV‑targeted rapamycin and controls, despite correct nanoparticle delivery (verified by fluorescence).
  • SGN‑targeted Rheb^CA fails to increase p‑S6K or neurite length, or exacerbates SGN loss.
  • Combined treatment does not improve ABR thresholds beyond systemic rapamycin alone. Any of these outcomes would refute the compartment‑specific mTOR setpoint hypothesis and suggest that alternative mechanisms (e.g., vascular stiffness, immune‑mediated damage) dominate age‑related hearing loss.